- Home
- TC vs CURX Comparison
TC vs CURX Comparison
Compare TC & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TC | CURX |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 29.7M |
| IPO Year | 2018 | 2025 |
Fundamental Metrics
Financial Performance| Metric | TC | CURX |
|---|---|---|
| Price | $12.50 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 2.7M |
| Earning Date | 12-16-2025 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,115,721.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.20 | $3.61 |
| 52 Week High | $39.00 | $8.60 |
Technical Indicators
Market Signals| Indicator | TC | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 25.45 | N/A |
| Support Level | $14.43 | N/A |
| Resistance Level | $15.88 | N/A |
| Average True Range (ATR) | 1.50 | 0.00 |
| MACD | -0.54 | 0.00 |
| Stochastic Oscillator | 23.66 | 0.00 |
Price Performance
Historical ComparisonAbout TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.